BMS's Opdivo could unseat Yervoy with Phase III melanoma survival
This article was originally published in Scrip
Executive Summary
Overall survival results from the Phase III Checkmate-066 clinical trial for Bristol-Myers Squibb's Opdivo (nivolumab) show a statistically significant improvement versus dacarzabine chemotherapy and efficacy to rival the company's current immunotherapy blockbuster Yervoy (ipilimumab) in treatment-naïve BRAF wild-type advanced melanoma.